Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Gnant, M; Pfeiler, G; Stöger, H; Mlineritsch, B; Fitzal, F; Balic, M; Kwasny, W; Seifert, M; Stierer, M; Dubsky, P; Greil, R; Steger, G; Samonigg, H; Fesl, C; Jakesz, R.
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
Br J Cancer. 2013; 109(3):589-596
Doi: 10.1038/bjc.2013.367
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Balic Marija
- Samonigg Hellmut
- Stöger Herbert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We investigated whether body mass index (BMI) can be used as a predictive parameter indicating patients who benefit from extended aromatase inhibitor (AI) treatment. The ABCSG-6a trial re-randomised event-free postmenopausal hormone receptor-positive patients from the ABCSG-6 trial to receive either 3 additional years of endocrine therapy using anastrozole vs nil. In this retrospective analysis, we investigated the prognostic and predictive impact of BMI on disease outcome and safety. In all, 634 patients (177 normal weight, 307 overweight, and 150 obese) patients were included in this analysis. Normal weight patients with additional 3 years of anastrozole halved their risk of disease recurrence (disease-free survival (DFS) HR 0.48; P=0.02) and death (HR 0.45; P=0.06) and had only a fifth of the risk of distant metastases (HR 0.22; P=0.05) compared with normal weight patients without any further treatment. In contrast, overweight+obese patients derived no benefit from additional 3 years of anastrozole (DFS HR 0.93; P=0.68; distant recurrence-free survival HR 0.91; P=0.78; and OS HR 0.9; P=0.68). The possible predictive impact of BMI on extended endocrine treatment could be strengthened by a Cox regression interaction model between BMI and treatment (P=0.07). Body mass index may be used to predict outcome benefit of extended AI treatment in patients with receptor-positive breast cancer.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Antineoplastic Agents, Hormonal - administration & dosage
- Antineoplastic Agents, Hormonal - adverse effects
- Aromatase Inhibitors - administration & dosage
- Aromatase Inhibitors - adverse effects
- Body Mass Index -
- Breast Neoplasms - drug therapy
- Chemotherapy, Adjuvant -
- Drug Administration Schedule -
- Female -
- Humans -
- Middle Aged -
- Neoplasms, Hormone-Dependent - drug therapy
- Nitriles - administration & dosage
- Nitriles - adverse effects
- Obesity - physiopathology
- Overweight - physiopathology
- Postmenopause -
- Retrospective Studies -
- Triazoles - administration & dosage
- Triazoles - adverse effects
- Young Adult -
- Find related publications in this database (Keywords)
- breast cancer
- endocrine therapy
- BMI
- aromatase inhibitor
- extended therapy
- obesity